Back

Identification of patients eligible for treatment with semaglutide after an acute coronary syndrome according to guidelines recommendations

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Challenges of managing obesity in cardiovascular disease Obesity ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Alberto Cordero

Hospital San Juan de Alicante, Alicante (Spain)

5 More presentations in this session

Presentation thumbnail
How excess fat affects cardiac electrophysiology: preclinical obesity, clinical obesity with cardiac arrhythmias and ECG features
Doctor N. Zhang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Childhood adiposity affects cardiac structure, function and disease risk in later life: evidence of a causal association
Doctor D. Du (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Beyond BMI: the predictive value of body roundness index for premature all-cause and cardiovascular mortality: a national cohort study of US adults under 65
Doctor S. Abohashem (Boston, US)
Abstract Slides Video
Presentation thumbnail
Implications of obesity and metabolic health on coronary heart disease: an analysis of 157,159 participants in the UK Biobank
Doctor R. Ananda (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Adiposity-related anthropometrics, cardiovascular outcomes, and finerenone in heart failure and chronic kidney disease with type 2 diabetes: a FINE-HEART analysis
Doctor J. Ostrominski (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Challenges of managing obesity in cardiovascular disease
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes.
thumbnail
Congress Presentation
Eligibility for semaglutide according to the SELECT trial in a Portuguese cohort of acute coronary syndrome
thumbnail
Congress Presentation
5-year risk of progression to type 2 diabetes in patients with myocardial infarction and overweight or obesity: a cohort study of the preventive potential of semaglutide treatment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources